.svg?noresize){kind=small}
Ultromics provides AI powered models that help institutions identify HFpEF and screen for cardiac amyloidosis.
Working with leading research institutions including Mayo Clinic, University of Oxford, University of Chicago Medicine, and other academic collaborators to advance cardiovascular science.
Ultromics enables clinicians to identify patients with HFpEF and cardiac amyloidosis from routine echocardiograms. Designed to fit seamlessly into existing workflows, helping support earlier diagnosis without additional imaging.
Used by leading health systems including University Hospitals, City of Hope, University of Winconstin, University of Chicago Medicine, and UT Southwestern.
Ultromics supports life sciences partners in detecting heart failure and screening for cardiac amyloidosis from routine echocardiography. Designed to support patient identification, clinical research and real-world evidence generation.
Working with organizations including Johnson & Johnson Innovative Medicine and Pfizer to advance research into cardiovascular disease and emerging therapies.
Ultromics contributes to clinical evidence generation, regulatory development and professional guidance for AI in echocardiography.
This work is supported through collaborations with organizations including the FDA TAP Program, FNIH and the American Society of Echocardiography.
.svg?noresize){kind=small}
-1.svg?noresize)
Deploy clinically validated AI within your existing imaging workflow to detect heart failure and screen for cardiac amyloidosis, without requiring additional scans or changes to how clinicians work.
